#1 Clinical Trials Search in Europe
EU – Europe
AT – Austria
HR – Croatia
CZ – Czech Republic
DK – Denmark
EE – Estonia
FI – Finland
FR – France
DE – Germany
IS – Iceland
IT – Italy
LV – Latvia
LT – Lithuania
NL – Netherlands
NO – Norway
PL – Poland
PT – Portugal
RO – Romania
SK – Slovakia
SI – Slovenia
ES – Spain
SE – Sweden
  • Find a Clinical Trial

    Search Trials by Disease

    Non-small cell lung cancer Breast cancer Plasma cell myeloma Neoplasm Neoplasm malignant Acute myeloid leukaemia Colitis ulcerative Obesity Colorectal cancer metastatic Prostate cancer Crohn's disease Dementia Alzheimer's type Colorectal cancer Ovarian cancer Hepatocellular carcinoma Breast cancer metastatic Dermatitis atopic Asthma Non-small cell lung cancer metastatic Malignant melanoma More trials…
  • Rare Diseases Treatments

    Search Trials by Disease

    Turner's syndrome Anti-HLA antibody test positive Amyloidosis Congenital disorder of glycosylation Neuroendocrine carcinoma of the skin Blastic plasmacytoid dendritic cell neoplasia Epstein-Barr virus infection Ventricular tachycardia Soft tissue sarcoma Autologous haematopoietic stem cell transplant Acquired ATTR amyloidosis Tourette's disorder Methylmalonic acidaemia Rhabdoid tumour Pneumonia More trials…

    Learn about Rare Diseases

    Inclusion body myositis – Trials in Disease Undifferentiated sarcoma Loeys-Dietz syndrome – Life with Disease Mantle cell lymphoma – Treatment Chondrosarcoma – Treatment Mucopolysaccharidosis III – Treatment Glomerulonephritis membranoproliferative – Life with Disease Phenylketonuria Mucous membrane pemphigoid – Trials in Disease Glycogen storage disease type V More diseases
  • Vaccine Clinical Trials
  • Pediatric Clinical Trials
  • Resources for Patients

    Browse Innovative Treatments

    Crgd-Zw800-1 Ribonucleic Acid K30 AUR200 Cetrelimab Pioglitazone Setanaxib Chlorhexidine Dihydrochloride Acalabrutinib Imipenem Anhydrate Deucrictibant Tralokinumab Transcon Il-2Β/Γ Trospium Chloride Liquid Paraffin Etamsylate Mva-Hbvac Trifluridine Acoramidis Hydrochloride Mosaic Hbcoreag Anhydrous Azithromycin More therapies…

    Learn about Your Condition

    Round cell liposarcoma Small intestine adenocarcinoma Retinitis pigmentosa Bone marrow disorder Periarthritis Clinically isolated syndrome Encephalitis autoimmune Colorectal adenoma Primary hyperthyroidism Supranuclear palsy Vomiting Sickle cell disease Herpes simplex meningitis Ovarian cancer stage III Optic glioma More diseases
  • Healthy Volunteers
  • Patient Guide
  • Our Partners
  • About Us
  • Contact us
  • Region
    🇪🇺 Europe
    🇦🇹 Austria
    🇭🇷 Croatia
    🇨🇿 Czech Republic
    🇩🇰 Denmark
    🇪🇪 Estonia
    🇫🇮 Finland
    🇫🇷 France
    🇩🇪 Germany
    🇮🇸 Iceland
    🇮🇹 Italy
    🇱🇻 Latvia
    🇱🇹 Lithuania
    🇳🇱 Netherlands
    🇳🇴 Norway
    🇵🇱 Poland
    🇵🇹 Portugal
    🇷🇴 Romania
    🇸🇰 Slovakia
    🇸🇮 Slovenia
    🇪🇸 Spain
    🇸🇪 Sweden

ABM

  • Study on Adding Elacestrant to Olaparib for Patients with HR-Positive, HER2-Negative Advanced Breast Cancer with gBRCA1/2 Mutations

    Recruiting

    2 1 1 1
    Investigated Drugs:
    • Elacestrant Dihydrochloride
    • Olaparib
    Germany

  • Long-term Safety Study of Delandistrogene Moxeparvovec for Patients with Duchenne Muscular Dystrophy Who Previously Received SRP-9001

    Recruiting

    3 1 1
    Investigated Diseases:
    • Duchenne muscular dystrophy
    Investigated Drugs:
    • Delandistrogene Moxeparvovec
    Belgium Germany Italy Spain

  • Study on Early Detection of Side Effects in Metastatic Melanoma Patients Using Zirconium (89Zr) Crefmirlimab Berdoxam Imaging

    Recruiting

    2 1 1
    Investigated Diseases:
    • Malignant melanoma
    Investigated Drugs:
    • Zirconium (89Zr) Crefmirlimab Berdoxam
    Germany

  • Long-term Safety Study of Tadalafil and Macitentan for Patients with Pulmonary Arterial Hypertension or Chronic Thromboembolic Pulmonary Hypertension

    Recruiting

    3 1 1 1
    Investigated Drugs:
    • Macitentan
    • Selexipag
    • Tadalafil
    Bulgaria France Hungary Poland

  • Study on the Effectiveness of Ozanimod for Children with Moderate to Severe Ulcerative Colitis Not Responding to Usual Treatment

    Recruiting

    4 1 1
    Investigated Diseases:
    • Colitis ulcerative
    Investigated Drugs:
    • Ozanimod
    Belgium France Germany Poland Spain

  • Study on Durvalumab, Etoposide, and Platinum Drug Combination for First-Line Treatment of Advanced Large-Cell Neuroendocrine Lung Cancer Patients

    Recruiting

    2 1 1 1
    Investigated Diseases:
    • Neuroendocrine tumour of the lung
    Investigated Drugs:
    • Carboplatin
    • Cisplatin
    • Durvalumab
    France
Previous Page
1 … 448 449 450 451 452 … 1,653
Next Page

Investigational Drugs in This Location

See which drug candidates are part of clinical trials near you. Click for detailed trial information.

Medical Conditions Being Studied in This Location

Explore diseases currently included in clinical trials near you. Click to view trials and details for each condition.

European Clinical Trials Information Network

The European Clinical Trials Information Network is transforming access to clinical trial information for patients across Europe. By overcoming language barriers, our platform allows everyone, regardless of their native language, to easily find relevant and comprehensible clinical trial data. This innovative service connects patients to cutting-edge treatments, creating a unified European community where health and progress transcend borders.

This service is not affiliated with the European Commission, the EMA, or the official CTIS system. Most information comes from publicly available international clinical-trial registries, supplemented by data from academic centres, national regulators, and commercial sponsors. We aim to keep all content accurate and up to date.

Explore the full ecosystem of clinical research in Europe.

The information provided on this website is mainly derived from international public clinical trial databases (CTIS.eu). In addition, we are including supplementary sources, such as information provided by academic centers and national regulators, as well as information supplied by commercial sponsors (pharmaceutical companies and contract research organizations). We try to ensure that the information provided is accurate and up to date.

Certain content and visual elements on this website have been generated or enhanced using artificial intelligence (AI).

The website is published by:
CTIN POLAND sp. z o.o.
with its registered office in Warsaw,
ul. rtm. Witolda Pileckiego 67/109,
02-781 Warsaw, Poland,
entered in the Register of Entrepreneurs of the National Court Register under KRS number 0001111334,
REGON: 528919042, NIP (Tax ID): 9512598637
Contact us

© 2026 CTIN Poland

Privacy Policy

Terms and Conditions

Contact

For Sites and Sponsors

Clinical Trial Locations

We use cookies

The website uses cookies to ensure the proper functioning of the site and to analyze internet traffic. Some cookies are essential for using the service and do not require consent. You can accept all cookies or use only the essential ones. Data is processed in accordance with our Privacy Policy. You have the right to withdraw your consent, access, rectify, delete, or limit the processing of your data at any time.
Numer nieprawidłowy!
Numer nieprawidłowy!